系统性免疫抑制剂停用或减量与他克莫司相关HSCT后睑板腺功能障碍进展相关
结果显示coGVHD严重度改善但睑板腺面积比(MGAR)无显著变化,而不伴coGVHD组MGAR下降;系统性免疫抑制剂停用或减量在两组均与MGAR恶化相关。
要点
- coGVHD改善不一定伴随睑板腺功能障碍改善。
- 系统性免疫抑制剂停用或减量与他克莫司后MGAR恶化相关。
- 不伴coGVHD患者随访末MGAR较基线显著下降。
核心结论
- coGVHD的改善不一定伴随睑板腺功能障碍的改善。
- 系统性免疫抑制剂停用或减量与他克莫司后睑板腺功能障碍进展相关。
研究设计与样本
- 48例(92眼)伴coGVHD,20例(40眼)不伴coGVHD。
- 随访时间自首次就诊起为22.9±10.7个月,coGVHD组与非coGVHD组分别为23.6±10.8个月与21.3±10.5个月(P=.441)。
主要发现
- coGVHD组末次随访ICCGVHD评分较基线改善(7.3±2.3 vs 8.5±1.7,P<.001),但MGAR无显著变化(51.7%±14.8% vs 52.6%±14.8%,P=.341)。
- coGVHD组MGAR稳定59眼(64.1%)、恶化14眼(15.2%)、改善19眼(20.7%)。
- 非coGVHD组ICCGVHD评分较基线稳定,但MGAR末次随访下降(70.2±11.0% vs 73.5±10.0%,P=.001)。
- 系统性免疫抑制剂停用或减量与MGAR恶化相关:coGVHD组OR 4.60(95%CI 1.24-17.00),非coGVHD组OR 2.48(95%CI 1.14-5.40)。
- coGVHD患者中停用或减量亚组的睑脂质量显著恶化(8.4±5.3 vs 5.9±4.6,P=.005)。
关键数值与推荐
- 主要结局指标为MGAR变化。
- coGVHD组末次随访ICCGVHD评分为7.3±2.3,基线为8.5±1.7(P<.001)。
- coGVHD组MGAR末次随访为51.7%±14.8%,基线为52.6%±14.8%(P=.341)。
- 非coGVHD组MGAR末次随访为70.2±11.0%,基线为73.5±10.0%(P=.001)。
临床怎么用
- 异基因造血干细胞移植后患者即使coGVHD改善,仍需关注睑板腺功能障碍的进展。
- 系统性免疫抑制剂停用或减量期间应监测睑板腺结构与功能变化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To observe the longitudinal changes in meibomian gland structure and function in patients after allogeneic hematopoietic stem cell transplantation (allo-HSCT) and to investigate the potential associated factors. DESIGN: Single-center retrospective clinical cohort study. PARTICIPANTS: Sixty-eight patients after allo-HSCT, including 48 patients (92 eyes) with and 20 patients (40 eyes) without chronic ocular graft-versus-host disease (coGVHD). METHODS: Medical records were retrospectively reviewed. Data collected included demographic characteristics, medical history, ocular surface disease index questionnaire, corneal fluorescein staining, bulbar conjunctival injection, Schirmer's test, noninvasive break-up time, lid margin abnormalities, meibum quality scores, and meibomian gland area ratio (MGAR). Follow-up data were compared. A generalized estimating equation was used to analyze the associated factors. MAIN OUTCOME MEASURES: Change in MGAR. RESULTS: All patients were followed up for 22.9 ± 10.7 months since first visit (coGVHD group vs non-coGVHD group = 23.6 ± 10.8 months vs 21.3 ± 10.5 months, P = .441). Compared with baseline, the severity of coGVHD at the last follow-up visit improved (International Chronic Ocular Graft-versus-Host Disease [ICCGVHD] score: 7.3 ± 2.3 vs 8.5 ± 1.7, P < .001), but no significant change in MGAR (51.7% ± 14.8% vs 52.6% ± 14.8%, P = .341). Specifically, MGAR remained stable in 59 eyes (64.1%), deteriorated in 14 eyes (15.2%), and improved in 19 eyes (20.7%). In the non-coGVHD group, while ICCGVHD scores remained stable compared to baseline, MGAR showed a decrease at the final follow-up (70.2 ± 11.0% vs 73.5 ± 10.0%, P = .001). Cessation or tapering of systemic immunosuppressants was associated with MGAR worsening in both the coGHVD group (odds ratio [OR]: 4.60, 95% confidence interval [CI]: 1.24-17.00) and the non-coGHVD group (OR: 2.48, 95%CI: 1.14-5.40). Further subgroup analysis revealed that in coGVHD patients, the subgroup with cessation or tapering of systemic immunosuppressants showed a significant worsening in meibum quality (8.4 ± 5.3 vs 5.9 ± 4.6, P = .005). CONCLUSIONS: Improvement in coGVHD is not necessarily accompanied by improvement in Meibomian gland dysfunction (MGD). Cessation or tapering of systemic immunosuppressants was associated with the progression of MGD after allo-HSCT.
引用
- Zhao W, Luo X, Yang J, et al. Systemic Immunosuppressant Cessation/Tapering Linked to MGD Progression Post-HSCT. Am J Ophthalmol. 2026. PMID: 41780738. doi:10.1016/j.ajo.2026.02.048
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。